問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Others-

Division of General Internal Medicine

更新時間：2023-09-19

田蕙芬-, -
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

68Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

田蕙芬

List

131Cases

2016-10-26 - 2019-07-31

Phase II/III

A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Talacotuzumab

Participate Sites
5Sites

Terminated4Sites

2014-03-19 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-12-01 - 2025-06-16

Phase III

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax Venetoclax

Participate Sites
4Sites

Recruiting4Sites

2017-08-01 - 2023-05-31

Phase III

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax (ABT-199/GDC-0199)

Participate Sites
5Sites

Terminated4Sites

2013-11-01 - 2018-11-30

Phase III

A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

  • Condition/Disease

    CHRONIC LYMPHOCYTIC LEUKEMIA

  • Test Drug

    GDC-0199(ABT-199)

Participate Sites
7Sites

Terminated7Sites

2020-09-30 - 2021-05-27

Phase I

A First In Human Study of the MCL-1 Inhibitor, ABBV-467

  • Condition/Disease

    relapsed/refractory multiple myeloma (MM)/Acute myeloid leukemia(AML)

  • Test Drug

    ABBV-467

Participate Sites
2Sites

Terminated2Sites

2009-03-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-03-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-09-01 - 2026-10-02

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAiVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS

  • Condition/Disease

    Myelodysplastic Syndromes

  • Test Drug

    Luspatercept; Epoetin alfa

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

2016-05-10 - 2022-05-31

Phase III

A phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission.

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Oral Azacitidine (CC-486)

Participate Sites
6Sites

Terminated5Sites

1 7 8 9 10 11 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB